Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
Applied Molecular Transport Inc. (AMTI) has announced a live conference call on July 6, 2022, at 8:30 a.m. ET, to share top-line data from its Phase 2 MARKET combination trial of AMT-101, targeting moderate-to-severe ulcerative colitis. This oral biologic product candidate combines IL-10 with anti-TNFα in biologic-naïve patients. Interested investors can join via phone or watch a live webcast on the company’s website, which will also host an archived replay for 30 days.
- Conference call scheduled to announce results from Phase 2 MARKET trial, which could positively influence investor sentiment.
- Potential for AMT-101 to address a significant need in treating moderate-to-severe ulcerative colitis.
- Pending results of the Phase 2 trial create uncertainty regarding the efficacy and market potential of AMT-101.
Live Conference Call and Webcast on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT)
SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naïve patients with moderate-to-severe ulcerative colitis. The company will issue a premarket press release and host a live webcasted conference call on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT).
Conference Call & Webcast Information
To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast will be available on the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.
About Applied Molecular Transport Inc.
AMT is a clinical-stage biopharmaceutical company developing novel oral biologic product candidates, by leveraging its technology platform to design biologic product candidates in patient friendly oral dosage forms. AMT’s product candidates are designed to precisely target the relevant pathophysiology of disease. AMT’s proprietary technology platform is incorporated in its product candidates, exploiting existing natural cellular trafficking pathways to drive the active transport of diverse therapeutic modalities across the IE barrier. Active transport is an efficient mechanism that utilizes the cell’s own machinery to transport materials across the IE barrier.
AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.
Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com
Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
What is the purpose of the Phase 2 MARKET trial for AMT-101?
When will the results of the Phase 2 MARKET trial be announced?
How can investors participate in the AMTI conference call?
What are the implications of AMT-101 for ulcerative colitis treatment?
What is the stock symbol for Applied Molecular Transport?
